What is the recommended management for pulmonary hypertension caused by a right-to-left shunt?

Management of Right-to-Left Shunted Pulmonary Hypertension

VSD closure should NOT be performed in adults with severe PAH when PA systolic pressure exceeds two-thirds systemic, pulmonary vascular resistance exceeds two-thirds systemic, and/or a net right-to-left shunt is present 1.

Critical Distinction: Eisenmenger Syndrome vs. Therapeutic Shunting

The management approach fundamentally differs based on whether the right-to-left shunt represents:

1. Eisenmenger Physiology (Contraindication to Closure)

When congenital heart defects (VSD, ASD, PDA) have progressed to severe PAH with shunt reversal:

• Do not close the defect - the right-to-left shunt is now protective, decompressing the failing right ventricle 1
• Defect closure causes harm when PA systolic pressure >67% systemic or PVR >67% systemic 1
• These patients require PAH-targeted medical therapy and consideration for transplantation

Medical Management:

• Parenteral prostacyclin analogues to reduce RV afterload 2
• Dobutamine as preferred inotrope for RV failure 2
• IV diuretics for fluid optimization 2
• Vasopressors if needed to maintain systemic blood pressure 2

Transplantation Pathway:

• Patients with Eisenmenger syndrome require either bilateral lung transplantation with cardiac defect repair OR heart-lung transplantation 2
• Registry data initially favored heart-lung transplantation for VSD-associated PH, but recent experience supports bilateral lung transplantation with defect repair 2
• Refer for transplant evaluation after inadequate response to maximal medical therapy 2
• PVOD/PCH patients should be listed at diagnosis due to lack of effective medical treatments 2

2. Therapeutic Right-to-Left Shunting (Palliative Strategy)

For end-stage PAH without pre-existing cardiac defects, creating a controlled right-to-left shunt can be beneficial:

Optimal Shunt Characteristics:

• Target shunt flow of approximately 11% of cardiac output 3
• This increases cardiac output by 25% and systemic oxygen delivery by 23% 3
• Arterial O₂ saturation remains acceptable until shunt flow exceeds 18% 3

Available Interventional Options:

Atrial Septostomy:

• Balloon atrial septostomy may be considered after failure of maximal medical therapy (WHO-FC III-IV) 2
• High-risk procedure with unpredictable results if uncontrolled 4
• Atrial Flow Regulator (AFR) device provides adjustable, restricted flow with better safety profile 4

Potts Shunt (Reversed):

• Left pulmonary artery to descending aorta anastomosis 5
• Preserves upper body oxygenation while decompressing suprasystemic RV 5
• Novel unidirectional-valved shunt (UVS) approach shows promise in adolescents/young adults 5
• All patients in early series alive and transplant-free at median 6-month follow-up 5

Risk Stratification for Intervention

High-Risk Features Requiring ICU Management:

• Heart rate >110 beats/min 2
• Systolic blood pressure <90 mmHg 2
• Low urine output with rising lactate 2

Common Pitfalls

1. Attempting defect closure in established Eisenmenger syndrome - this eliminates the protective RV decompression mechanism and causes acute decompensation
2. Uncontrolled atrial septostomy - risks acute severe desaturation and death 4
3. Delayed transplant referral - refer after inadequate response to initial monotherapy, list after failure of maximal combination therapy 2
4. Underestimating severity - invasive hemodynamic assessment is essential before any intervention in adults 1

Prognosis Considerations

• PAH associated with CTD has worse prognosis than IPAH even with prostanoids 2
• PAH associated with CHD (Eisenmenger) has better survival than IPAH 2
• PVOD/PCH have poorest prognosis - list for transplant at diagnosis 2
• Post-transplant survival now 52-75% at 5 years and 45-66% at 10 years 2